Frontiers in Neurology
Diabetes drug may offer symptom benefits in Parkinson’s trial
A four-week randomized trial in 12 people found symptom-score changes differed across two diabetes drugs and placebo, with more favorable trends for dapagliflozin.A four-week randomized trial in 12 people found symptom-score changes differed across two diabetes drugs and placebo, with more favorable trends for dapagliflozin.
Randomized trial · 12 peopleParkinson's disease
Who was studied12 patients with Parkinson's disease or Lewy-body dementia, against placebo
What changedSymptom scores fell with dapagliflozin (median change −7.0 points) versus placebo (−3.5 points)
The catchBlood sugar changes could influence motor scores, but follow-up HbA1c measurements were missing